Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aims: Previous studies have reported an elevation in adiponectin concentrations using glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) therapy; however, this possible pleiotropic effect is still uncertain. Thus, the objective of this meta‐analysis of randomized controlled trials was to assess the impact of GLP‐1 RA on adiponectin levels. Methods: This systematic review and meta‐analysis included randomized controlled trials investigating the effect of GLP‐1 RA on circulating adiponectin concentrations. Studies from PubMed, Web of Science, Scopus, and Google Scholar databases were included. A random‐effects model and a sensitivity analysis using the leave 1‐out method were conducted. Results: A meta‐analysis of 20 randomized controlled trials involving 1497 individuals demonstrated a significant increase in adiponectin levels after GLP‐1 RA administration (weighted mean difference [WMD]: 0.59 μg/mL, 95% confidence interval [CI]: 0.10, 1.08, P = .02). Particularly, liraglutide had a significant effect on adiponectin (WMD: 0.55 μg/mL, 95% CI: 0.04, 1.06, P = .04), while exenatide did not affect these concentrations (WMD: 0.60 μg/mL, 95% CI: −0.23, 1.42, P = .16). Conclusion: GLP‐1 RA treatment is associated with an increase in adiponectin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“We applied the leave-one-out method to perform a sensitivity analysis and assess the individual study's impact on the overall effect size.(13) Finally, a funnel plot was performed to evaluate the presence of potential publication bias in the meta-analysis.”
MethodGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Mirza, S., Hossain, M., Mathews, C., Martinez, P., Pino, P., Gay, J. L., Rentfro, A., McCormick, J. B., & Fisher-Hoch, S. P. (2012) · Cytokine · doi:10.1016/j.cyto.2011.09.029 · Cited by 358
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · cited 1×
“….02 91% Bunck et al. 2010 0.71 [0.21, 1.20] .005 91% Derosa et al. 2012 0.70 [0.19, 1.21] .007 90% Dutour et al. 2016 0.64 [0.14, 1.15] .01 91% Elkind-Hirsch et al. 2008 0.69 [0.17, 1.21] .009 91% Fan et al. 2013 0.52 [0.03, 1.02] .04 91% Frøssing et al. 2018 0.70 [0.07, 1.33] .03 91% Ghanim…”
InfluentialDutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · cited 1×
“…1.05] .03 91% Bi et al. 2014 0.61 [0.10, 1.11] .02 91% Bunck et al. 2010 0.71 [0.21, 1.20] .005 91% Derosa et al. 2012 0.70 [0.19, 1.21] .007 90% Dutour et al. 2016 0.64 [0.14, 1.15] .01 91% Elkind-Hirsch et al. 2008 0.69 [0.17, 1.21] .009 91% Fan et al. 2013 0.52 [0.03, 1.02] .04 91% Frøssing…”
InfluentialYan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Liang, Z., Wu, Q., Chen, B., Yu, P., Zhao, H., & Ouyang, X. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.04.005 · Cited by 206 · cited 2×
“Trials enrolled subjects with type 2 diabetes, type 1 diabetes,(33) nonalcoholic steatohepatitis,(27) nonalcoholic fatty liver disease,(24,31) polycystic ovary syndrome(30,32) and hypertension.(18) The characteristics of the included studies are summarized in Table 1.”
BackgroundInfluentialEffect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178 · cited 1×
“….007 90% Dutour et al. 2016 0.64 [0.14, 1.15] .01 91% Elkind-Hirsch et al. 2008 0.69 [0.17, 1.21] .009 91% Fan et al. 2013 0.52 [0.03, 1.02] .04 91% Frøssing et al. 2018 0.70 [0.07, 1.33] .03 91% Ghanim et al. 2020 0.61 [0.10, 1.12] .02 91% Gurkan et al. 2014 0.64 [0.11, 1.18] .02 91% Li et al.…”
InfluentialBunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · cited 2×
“…CI) P value I2 Ahmadi et al. 2018 0.57 [0.07, 1.08] .02 91% Armstrong et al. 2016 0.55 [0.05, 1.05] .03 91% Bi et al. 2014 0.61 [0.10, 1.11] .02 91% Bunck et al. 2010 0.71 [0.21, 1.20] .005 91% Derosa et al. 2012 0.70 [0.19, 1.21] .007 90% Dutour et al. 2016 0.64 [0.14, 1.15] .01 91% Elkind-Hirsch…”
BackgroundInfluential
Cited by
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Moreover, a meta-analysis of 20 randomised controlled trials revealed that, independent of fat mass changes, liraglutide significantly increased circulating adiponectin levels [148].”
BackgroundGlucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Fiorenza, M., Checa, A., Sandsdal, R. M., Jensen, S. B. K., Juhl, C. R., Noer, M. H., Bogh, N. P., Lundgren, J. R., Janus, C., Stallknecht, B. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101629 · Cited by 14
Metadata
- Authors
- Simental‐Mendía, L. E., Sánchez‐García, A., Linden‐Torres, E., & Simental‐Mendía, M.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2021-04-29
- Volume
- 87
- Issue
- 11
- Pages
- 4140-4149
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W3139662819
- Cited by
- 59
- References
- 18
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.